| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 92.10M | — |
| Operating expense | — | — |
| Net income | -31.10M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, 2B30.F returned +12.8% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +19.0% |
| 1 year | +12.8% |
| 5 years | +221.2% |
| All-time high | €21.69 (Aug 2018) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in 2B30.F would be worth today ›No. Xeris Biopharma Holdings, Inc. has not paid a dividend in the past 12 months.
Xeris Biopharma Holdings, Inc. is part of the Healthcare sector.
Xeris Biopharma Holdings, Inc. has a market cap of 1.34B EUR, based on the latest quote.
Xeris Biopharma Holdings, Inc. is expected to report earnings around Nov 5, 2026. That date is an estimate and has not been confirmed by the company.
